Eurofins Launches Third Buy-Back Programme of Its Own Shares
2024年9月2日 - 2:15PM
ビジネスワイヤ（英語）
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific SE (the “Company”) (EUFI.PA) announces its
intention to launch a new buy-back programme of its own shares
(ISIN FR0014000MR3) for a maximum amount representing up to 2% of
its share capital. This third programme follows the first programme
that took place between 3 October 2022 and 8 August 2023 and the
second programme that took place between 25 October 2023 and 30
August 2024. The new programme is commencing on 02 September 2024
and will last until 31 August 2026. The Company may at any time
interrupt this programme in view of market conditions and/or the
evolution of its investment strategy.
The shares to be purchased under this programme will be
primarily used to hedge the Company’s Long-Term Incentive plans but
may also be cancelled, used to partially finance acquisitions or
for other purposes approved by the Board of Directors and within
the authorization of the EGM.
The Company is mandating an independent provider of financial
services to execute the first tranche of this programme for a
maximum duration of one month starting on 02 September 2024 and
ending on 30 September 2024 with a maximum volume of 1,470,000
shares or 0.76% of its share capital.
Over the course of the second share buy-back programme,
2,700,000 shares were repurchased, representing 1.40% of the
current share capital.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific S.E.
network of independent companies believes that it is a global
leader in food, environment, pharmaceutical and cosmetic product
testing and in discovery pharmacology, forensics, advanced material
sciences and agroscience contract research services. It is also one
of the market leaders in certain testing and laboratory services
for genomics, and in the support of clinical studies, as well as in
biopharma contract development and manufacturing. It also has a
rapidly developing presence in highly specialised and molecular
clinical diagnostic testing and in-vitro diagnostic products.
With ca. 62,000 staff across a decentralised and entrepreneurial
network of more than 900 laboratories in over 1,000 companies in 62
countries, Eurofins offers a portfolio of over 200,000 analytical
methods to evaluate the safety, identity, composition,
authenticity, origin, traceability and purity of a wide range of
products, as well as providing innovative clinical diagnostic
testing services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for
the health and safety of people and our planet. The ongoing
investment to become fully digital and maintain the best network of
state-of-the-art laboratories and equipment supports our objective
to provide our customers with high-quality services, innovative
solutions and accurate results in the best possible turnaround time
(TAT). Eurofins companies are well positioned to support clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
evolving requirements of healthcare practitioners around the
world.
The Eurofins network has grown very strongly since its inception
and its strategy is to continue expanding its technology portfolio
and its geographic reach. Through R&D and acquisitions, its
companies draw on the latest developments in the field of
biotechnology and analytical chemistry to offer their clients
unique analytical solutions.
Shares in Eurofins Scientific S.E. are listed on the Euronext
Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg
ERF FP).
Until it has been lawfully made public widely by Eurofins
Scientific S.E. through approved distribution channels, this
document contains inside information for the purpose of Regulation
(EU) 596/2014 of the European Parliament and of the Council of 16
April 2014 on market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific S.E.’s management as of the date of this
release. These forward-looking statements are not guarantees for
future performance, and the forward-looking events discussed in
this release may not occur. Eurofins Scientific S.E. disclaims any
intent or obligation to update any of these forward-looking
statements and estimates. All statements and estimates are made
based on the information available to the Company’s management as
of the date of publication, but no guarantees can be made as to
their completeness or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240901275971/en/
Notes to Editors: For more information, please
visit www.eurofins.com or contact: Investor Relations
Eurofins Scientific SE Phone: +32 2 766 1620 E-mail:
ir@sc.eurofinseu.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 12 2024 まで 1 2025
Enerplus (NYSE:ERF)
過去 株価チャート
から 1 2024 まで 1 2025
